Facetten
Zugriff
Einrichtung
Medientyp
- Text 52
Karte
Erscheinungsjahr
Autor/in
- Weisel, Katja
- Moreau, Philippe 7
- Bokemeyer, Carsten 6
- Goldschmidt, Hartmut 6
- Cavo, Michele 5
- alle zeigen
Sprache
52 Einträge gefunden
-
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
- Dimopoulos, Meletios
- Weisel, Katja
- Moreau, Philippe
- Anderson, Larry D
- White, Darrell
- San-Miguel, Jesus
- Sonneveld, Pieter
-
-
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
- Rodriguez-Otero, Paula
- Ayers, Dieter
- Cope, Shannon
- Davies, Faith E
- Delforge, Michel
- Mojebi, Ali
- Jansen, Jeroen P
-
Selective elimination of immunosuppressive T cells in patients with multiple myeloma
- Awwad, Mohamed H S
- Mahmoud, Abdelrahman
- Bruns, Heiko
- Echchannaoui, Hakim
- Kriegsmann, Katharina
- Lutz, Raphael
- Raab, Marc S
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
- Nooka, Ajay K
- Weisel, Katja
- van de Donk, Niels Wcj
- Routledge, David
- Otero, Paula Rodriguez
- Song, Kevin
- Quach, Hang
-
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
- Avet-Loiseau, Hervé
- San-Miguel, Jesus
- Casneuf, Tineke
- Iida, Shinsuke
- Lonial, Sagar
- Usmani, Saad Z
- Spencer, Andrew
-
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
- Weisel, Katja
- Mateos, Maria-Victoria
- Gay, Francesca
- Delforge, Michel
- Cook, Gordon
- Szabo, Zsolt
- Desgraz, Renaud
-
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
- Vij, Ravi
- Nath, Rajneesh
- Afar, Daniel E H
- Mateos, Maria Victoria
- Berdeja, Jesus G
- Raab, Marc S
- Guenther, Andreas
-
-
-
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
- Dimopoulos, Meletios A
- Niesvizky, Ruben
- Weisel, Katja
- Siegel, David S
- Hajek, Roman
- Mateos, María-Victoria
- Cavo, Michele
-
-
-
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
- Raab, Marc S
- Engelhardt, Monika
- Blank, Antje
- Goldschmidt, Hartmut
- Agis, Hermine
- Blau, Igor W
- Einsele, Hermann
-
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
- Ludwig, Heinz
- Pönisch, Wolfram
- Knop, Stefan
- Egle, Alexander
- Hinke, Axel
- Schreder, Martin
- Lechner, Daniel
-
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- Mateos, Maria-Victoria
- Spencer, Andrew
- Nooka, Ajay K
- Pour, Ludek
- Weisel, Katja
- Cavo, Michele
- Laubach, Jacob P
-
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
- Weisel, Katja
- Majer, Istvan
- DeCosta, Lucy
- Oriol, Albert
- Goldschmidt, Hartmut
- Ludwig, Heinz
- Campioni, Marco